title: Genotoxic therapy stimulates error-prone DNA repair in dormant hepatocellular cancer stem cells.
abstract: Previous studies have described distinct dormant and proliferating populations of cancer stem cells in hepatocellular carcinoma. The CD13 protein is involved in the scavenging of reactive oxygen species through the glutathione reductase pathway and is associated with resistance to chemotherapy. Whereas CD13(-) proliferating cancer stem cells are sensitive to chemotherapy, CD13(+) dormant cancer stem cells are associated with the development of resistance to chemotherapy. CD13(+) cells in hypoxic areas of the tumour survive chemotherapy, leading to subsequent disease relapse and metastasis. Whether CD13(+) dormant cells simply resume proliferation following therapy or whether they also acquire greater malignant potential, remains unknown. The mechanisms involved also remain unclear. In the present study, we investigated the repair of DNA damage in CD13(+) dormant and CD13(-) proliferating cells. Total RNA was extracted from tissues, and quantitative real-time polymerase chain reaction (PCR) was performed for specific genes and GAPDH following PCR. Products were then subjected to a temperature gradient of 55-95°C with continuous fluorescence monitoring to generate a melting curve. Cells were incubated with primary antibodies, washed twice, incubated with fluorescent-labelled secondary antibodies for 30 min on ice and analyzed by flow cytometry. The results revealed that the repair of DNA damage in CD13(+) dormant cells occurs predominantly through non-homologous end-joining, a repair process that is error-prone, whereas CD13(-) proliferating cells primarily utilise high-fidelity homologous recombination for DNA repair. These data indicate that not only is dormancy a protective mechanism for cancer stem cells to survive therapy, but it also enhances the generation and accumulation of mutations following DNA damage. Therefore, the CD13(+) dormant cancer stem cells must be eradicated fully to achieve complete remission of cancer.
authors.affiliation: Departments of Frontier Science for Cancer and Chemotherapy, and.
authors.forename: Shimpei
authors.initials: S
authors.lastname: Nishikawa
authors.forename: Hideshi
authors.initials: H
authors.lastname: Ishii
authors.forename: Naotsugu
authors.initials: N
authors.lastname: Haraguchi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kano
authors.forename: Takahito
authors.initials: T
authors.lastname: Fukusumi
authors.forename: Katsuya
authors.initials: K
authors.lastname: Ohta
authors.forename: Miyuki
authors.initials: M
authors.lastname: Ozaki
authors.forename: Daisuke
authors.initials: D
authors.lastname: Sakai
authors.forename: Taroh
authors.initials: T
authors.lastname: Satoh
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori